Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease.
18 January 2019
Creative Dialogue Hub for Digital Innovation in Greifswald
14 January 2019
EHealth SMEs for Partnership in the Baltic Sea Region